
Is NOVN (Novan, Inc.) Halal or Haram?
While Novan's biotechnology focus is inherently halal, the company's financial structure renders it non-compliant according to AAOIFI standards. Specifically, its interest-bearing debt load is excessive at 1 49.1% of its market cap, and its liquidity ratio is extremely high at 467.2 %, far exceeding the 33% threshold for both metrics.
NOVN — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2023-08-21 | 0.06 | 0.07 | 0.05 | 0.06 | 114K | +0.54% |
| 2023-08-18 | 0.06 | 0.07 | 0.04 | 0.05 | 169K | -15.57% |
| 2023-08-17 | 0.06 | 0.07 | 0.06 | 0.06 | 45K | +9.71% |
| 2023-08-16 | 0.05 | 0.08 | 0.05 | 0.06 | 184K | +11.20% |
| 2023-08-15 | 0.05 | 0.05 | 0.05 | 0.05 | 107K | +0.00% |
| 2023-08-14 | 0.05 | 0.06 | 0.05 | 0.05 | 120K | +0.60% |
| 2023-08-11 | 0.05 | 0.07 | 0.05 | 0.06 | 124K | +9.78% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for NOVN
Business Activity
Permissible
Novan passes the business activity screen as its core operations involve developing nitric oxide-based therapies for dermatological conditions like acne and viral skin infections, which are permissible.
Debt / Market Cap
149.08%
Interest Income
0.22%
Cash & Securities
467.18%
About Novan, Inc. (NOVN)
Novan, Inc. is a pre-commercial pharmaceutical company specializing in nitric oxide-based therapies for dermatology and anti-infective needs. Their pipeline includes specific candidates like SB204 for acne vulgaris and SB206, a topical anti-viral gel designed to treat viral skin infections. By focusing on proprietary technology to deliver nitric oxide, they aim to address unmet medical needs in treating fungal infections and inflammatory skin diseases .
For Muslim investors using HalalStocks.co.uk, Novan is currently classified as Not Halal (Haram). Although the company's business of creating medicine is permissible, it fails two critical financial screens under AAOIFI standards . The primary issue is the financial structure, where the ratios for both debt and cash holdings relative to market capitalization are significantly higher than the allowed 33% limit.
From a financial perspective, the company carries a debt-to-market cap ratio of 149.1%, indicating a heavy reliance on leverage that is incompatible with Islamic finance principles. Additionally , the company holds a disproportionately large amount of cash and interest-bearing securities compared to its market value (467. 2%), which is common for pre-revenue biotech firms but problematic for shariah compliance. Investors seeking halal options in the biotech sector should look for companies with tighter capital structures and less reliance on interest-based financing.
NOVN Key Financial Statistics
Revenue
$23.6M
Net Income
$-19.6M
EPS (Diluted)
$-0.89
Stock Price
0.09
Beta
-0.04
52-Week Range
0.082-3.33
Total Debt
$3.9M
Total Equity
$4.6M
Current Ratio
0.91
NOVN Financial Health & Profitability
Profit Margins
Revenue Growth (YoY)
+736.6%
Prior year: $2.8M
Net Cash
$8.4M
Cash: $12.3M — Debt: $3.9M
R&D Spending
$16.0M
% of Revenue
67.7%
Frequently Asked Questions About NOVN
Is NOVN (Novan, Inc.) stock halal to invest in?▾
What does Novan, Inc. do?▾
What screening criteria were used for NOVN?▾
When was NOVN last screened?▾
Disclaimer
This shariah compliance assessment for NOVN (Novan, Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-02-24.